The aim of our study was to evaluate repopulation rate of peripheral CD19+ B-cells, as well as other lymphocyte subtypes as a potential surrogate marker for individual application intervals in patients with MS and NMO/NMOSD treated with RTX. Here, CD19 is linked to myeloid sarcoma.